ArticleBMC cancer2018
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review.Cancer biology & medicine · 2024Pooled it
- Gastrointestinal cancers in women: The role of sex hormones.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- X-ray preactivated reversible persistent luminescence enables photodynamic immunotherapy of deep tumors.Nature communications · 2026Article
- Tumor Characteristics and Clinical Features of the Patient as Prognostic Factors in PDAC.Cancers · 2025Review
- Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation.PLoS computational biology · 2024Article
- Genes Co-Expressed withInternational journal of molecular sciences · 2024Article
- Unraveling dynamically encoded latent transcriptomic patterns in pancreatic cancer cells by topic modeling.Cell genomics · 2023Article
- Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment.Journal for immunotherapy of cancer · 2022Review
- A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study.Cancers · 2021Article
- Histological and transcriptional characterization of the pancreatic acinar tissue in type 1 diabetes.BMJ open diabetes research & care · 2021Article
- Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2020Article
- Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer.American journal of cancer research · 2020Article
- Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.Cancer medicine · 2019Article
- Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients.Aging · 2019Article
- Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma.Biomarker research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe relevance of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Clinical trials targeting ER with selective estrogen receptor modulators in pancreatic cancer did not show any benefit. Here, we analyze the impact of recently characterized ER isoform beta on survival in a cohort of patients with resected PDAC.
methodsEighty-four patients having undergone pancreatic resection for PDAC at a single institution were identified. Tissue microarrays were constructed of archival tumor specimens. The expression of ER beta was determined by immunohistochemistry and quantified by a system established for estrogen receptor expression in breast cancer. ER beta expression was then correlated with clinicopathological parameters, and univariate and multivariate survival analyses were performed.
resultsNuclear expression of ER beta was found in 31% of tumors. No significant correlation was found between ER beta expression and TNM status, tumor grade, age or sex. Univariate analysis revealed nodal metastasis and the expression of ER beta as factors correlating with a shorter overall survival and disease free survival. When comparing ER beta expression in patients surviving more than 24 months with those who died from the tumor within 12 or 24 months, respectively, a significantly lower ER beta expression was found in the long term survivors. In multivariate analysis, ER beta expression was demonstrated to be an independent predictor of shorter overall survival.
conclusionsIn resected PDAC, expression of ER beta seems to correlate with poor prognosis. These data may help to identify patients who may benefit from additional systemic therapy including selective estrogen receptor modulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.